loading
前日終値:
$61.34
開ける:
$61.11
24時間の取引高:
628.80K
Relative Volume:
1.04
時価総額:
$3.80B
収益:
$112.53M
当期純損益:
$-258.91M
株価収益率:
-14.26
EPS:
-4.33
ネットキャッシュフロー:
$-124.42M
1週間 パフォーマンス:
+6.76%
1か月 パフォーマンス:
+17.96%
6か月 パフォーマンス:
+20.99%
1年 パフォーマンス:
+60.57%
1日の値動き範囲:
Value
$60.92
$61.96
1週間の範囲:
Value
$56.12
$62.83
52週間の値動き範囲:
Value
$35.17
$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
名前
Rhythm Pharmaceuticals Inc
Name
セクター
Healthcare (1151)
Name
電話
857-264-4280
Name
住所
222 BERKELEY STREET, BOSTON, MA
Name
職員
283
Name
Twitter
@rhythmpharma
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
RYTM's Discussions on Twitter

RYTM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
61.74 3.80B 112.53M -258.91M -124.42M -4.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-07 アップグレード BofA Securities Neutral → Buy
2025-03-05 再開されました Stifel Buy
2025-01-02 開始されました Jefferies Buy
2024-12-20 開始されました Oppenheimer Outperform
2024-10-21 開始されました Guggenheim Buy
2024-09-18 開始されました H.C. Wainwright Buy
2024-09-17 開始されました JMP Securities Mkt Outperform
2024-05-08 ダウングレード BofA Securities Buy → Neutral
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-08-01 アップグレード BofA Securities Neutral → Buy
2023-01-18 再開されました Canaccord Genuity Buy
2022-08-08 アップグレード Goldman Neutral → Buy
2022-08-05 アップグレード BofA Securities Underperform → Neutral
2022-06-17 繰り返されました Needham Buy
2022-03-02 再開されました Stifel Buy
2022-02-17 アップグレード Ladenburg Thalmann Neutral → Buy
2021-12-08 開始されました Wells Fargo Overweight
2021-11-19 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-14 再開されました Goldman Neutral
2021-08-04 ダウングレード BofA Securities Neutral → Underperform
2021-08-04 ダウングレード Ladenburg Thalmann Buy → Neutral
2020-11-30 ダウングレード BofA Securities Buy → Neutral
2020-01-08 開始されました Goldman Sell
2019-07-12 アップグレード Stifel Hold → Buy
2019-07-08 開始されました Canaccord Genuity Buy
2019-03-13 開始されました Ladenburg Thalmann Buy
2018-09-07 再開されました Morgan Stanley Overweight
2018-06-25 繰り返されました Needham Buy
2018-06-15 繰り返されました Needham Buy
2017-10-30 開始されました BofA/Merrill Buy
2017-10-30 開始されました Needham Buy
すべてを表示

Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース

pulisher
Apr 15, 2025

Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 13, 2025

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded at Bank of America - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com

Apr 10, 2025
pulisher
Apr 09, 2025

Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter

Apr 08, 2025
pulisher
Apr 08, 2025

Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView

Apr 08, 2025
pulisher
Apr 08, 2025

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK

Apr 08, 2025
pulisher
Apr 08, 2025

Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks

Apr 08, 2025
pulisher
Apr 07, 2025

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals’ Unexpected Surge: A Stock to Watch? - timothysykes.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma's drug for rare obesity meets late-stage trial goal - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Reports Promising Phase 3 Trial Re - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Achieves Phase 3 Trial Success wit - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals stock rises on trial success By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals stock rises on trial success - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire

Apr 07, 2025

Rhythm Pharmaceuticals Inc (RYTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):